Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

HEPA | Hepion Pharmaceuticals, Inc.

Index- P/E- EPS (ttm)-12.01 Insider Own0.15% Shs Outstand3.84M Perf Week-4.38%
Market Cap20.28M Forward P/E- EPS next Y-6.36 Insider Trans105.11% Shs Float3.83M Perf Month-31.33%
Income-45.80M PEG- EPS next Q-1.64 Inst Own9.40% Short Float / Ratio7.98% / 10.57 Perf Quarter-55.54%
Sales- P/S- EPS this Y-27.80% Inst Trans-48.73% Short Interest0.31M Perf Half Y-62.81%
Book/sh6.45 P/B0.78 EPS next Y29.30% ROA-84.90% Target Price41.00 Perf Year-55.95%
Cash/sh7.55 P/C0.66 EPS next 5Y- ROE-110.50% 52W Range5.20 - 23.85 Perf YTD-16.42%
Dividend- P/FCF- EPS past 5Y59.00% ROI- 52W High-78.96% Beta1.72
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin- 52W Low-3.46% ATR0.49
Employees25 Current Ratio4.30 Sales Q/Q- Oper. Margin- RSI (14)28.07 Volatility7.76% 7.57%
OptionableNo Debt/Eq0.00 EPS Q/Q29.60% Profit Margin- Rel Volume1.65 Prev Close5.45
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume28.93K Price5.02
Recom2.00 SMA20-22.80% SMA50-32.21% SMA200-55.21% Volume47,792 Change-7.89%
Date Action Analyst Rating Change Price Target Change
Jul-20-20Resumed ROTH Capital Buy $14
Sep-21-23 04:05PM
Sep-19-23 09:00AM
Sep-18-23 11:01AM
Sep-14-23 08:45AM
04:30PM Loading…
Sep-06-23 04:30PM
Jun-15-23 04:45PM
May-24-23 04:45PM
May-22-23 07:00AM
May-19-23 04:05PM
May-10-23 11:15AM
Apr-17-23 04:15PM
Mar-30-23 08:45AM
Mar-16-23 04:10PM
04:15PM Loading…
Mar-02-23 04:15PM
Feb-09-23 04:15PM
Jan-18-23 09:15AM
Jan-10-23 04:15PM
Jan-09-23 08:00AM
Jan-05-23 04:15PM
Dec-05-22 04:30PM
Nov-07-22 08:00AM
Nov-04-22 08:30AM
Nov-02-22 08:00AM
Oct-26-22 08:00AM
Oct-20-22 04:30PM
Oct-19-22 08:00AM
05:00PM Loading…
Sep-26-22 05:00PM
Sep-14-22 08:00AM
Sep-12-22 08:00AM
Sep-08-22 08:00AM
Aug-31-22 08:00AM
Jul-22-22 04:15PM
Jul-04-22 10:23AM
Jun-28-22 08:30AM
Jun-24-22 04:15PM
Jun-20-22 08:00AM
Jun-15-22 08:00AM
Jun-14-22 08:00AM
May-31-22 04:30PM
May-27-22 08:54AM
May-03-22 08:00AM
Mar-07-22 08:00AM
Feb-15-22 08:00AM
Feb-14-22 08:00AM
Jan-26-22 08:00AM
Jan-12-22 08:00AM
Jan-06-22 04:15PM
Jan-05-22 04:30PM
Dec-21-21 08:00AM
Nov-30-21 08:00AM
Nov-16-21 08:45AM
Nov-10-21 08:00AM
Nov-04-21 08:00AM
Nov-02-21 08:00AM
Oct-07-21 08:00AM
Sep-29-21 09:00AM
Sep-13-21 08:00AM
Sep-10-21 04:05PM
Aug-15-21 05:50AM
Jul-23-21 04:40PM
Jul-13-21 08:00AM
Jun-25-21 04:30PM
Jun-09-21 07:45AM
May-16-21 05:10AM
May-06-21 07:45AM
Apr-29-21 09:50AM
Mar-23-21 07:15AM
Mar-22-21 04:30PM
Mar-11-21 07:30AM
Feb-18-21 04:30PM
Feb-16-21 06:45AM
Feb-12-21 04:45PM
Feb-10-21 07:30AM
Feb-09-21 04:30PM
Feb-05-21 02:00AM
Jan-29-21 03:07PM
Jan-05-21 08:00AM
Dec-29-20 04:15PM
Dec-22-20 07:30AM
Dec-10-20 08:55AM
Dec-02-20 07:30AM
Nov-30-20 05:30PM
Nov-24-20 07:20PM
Nov-18-20 07:30AM
Nov-17-20 04:30PM
Nov-12-20 08:30AM
Nov-10-20 09:00AM
Nov-05-20 08:57AM
Oct-27-20 07:45AM
Oct-05-20 07:30AM
Sep-29-20 08:30AM
Sep-17-20 08:00AM
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wijngaard PeterDirectorSep 19Buy5.641,0005,6404,501Sep 20 11:27 AM
Foster Robert TCEO and DirectorSep 18Buy5.601,6008,96050,470Sep 19 09:01 AM
Wijngaard PeterDirectorSep 15Buy5.602,00011,2013,501Sep 20 11:27 AM
Foster Robert TCEO,CSO and DirectorSep 15Buy5.401,6008,64048,870Sep 18 08:00 AM